According to the latest announcement issued by Fosun Pharma, a company listed on the main board in September 19, Fosun Pharma will spin off its holding subsidiary, Shanghai Fu Honghanlin Biotechnology Co., Ltd. (hereinafter referred to as "Fu Honghanlin") and list it on the main board of the Hong Kong Stock Exchange. The expected listing time is September 25th, and the final issue price is set at HK$ 49.6 per share.
Chen Qiyu, chairman of Fosun Pharma, said in an interview with Securities Daily, "The next ten or even twenty years are destined to be the golden decade of China Biomedical Company for twenty years. I believe that Fu Honghanlin will strive to be one of the best, and contribute products with high quality, low price and high curative effect to more than 4 million new cancer patients in China and more than 10 million new cancer patients around the world every year. "
According to public information, Fu Honghanlin is a biopharmaceutical platform under Fosun Pharma. Established by Fosun Pharma and a team of overseas scientists in 20 10. Mainly focus on the research and development of monoclonal antibody drugs, products covering tumors and autoimmune diseases.